Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative study of Shingrix vaccination schedules in anti-CD20–treated MS and NMOSD patients
2025-525106-37-00Phase 4Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Zoster vaccine recombinant in multiple sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) and herpes zoster (HZ) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Primary humoral vaccine response rate. Planned start Jul 2026; status: authorised.
02
Drugs
Zoster vaccine recombinant
03
Conditions
multiple sclerosis (MS)Neuromyelitis Optica Spectrum Disorder (NMOSD)herpes zoster (HZ)
Beyond the preview
Go deeper on 2025-525106-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525106-37-00.